BAD is the biologically active metabolite of benzamide riboside and a potent inhibitor of inosine 5'-monophosphate dehydrogenase (IMPDH). It was also found to be a potent and competitive inhibitor of human NAD kinase (K_i = 90 µM) and, at higher concentration and to a lower extent, of the bacterial enzyme (Bonnac et al. 2007). Furthermore, BAD is a non-hydrolysable substrate/inhibitor of NADases and PARP enzymes. BAD was used in co-crystallization experiments with NADases (Strømland et al. 2021) and PARP1 (Langelier et al. 2018). References: Bonnac et al., Bioorg. Med. Chem. Lett., 17, 1512 - 1515 (2007); Langelier et al., Nat. Commun., 9(1):844 (2018); Strømland et al., Nat. Commun., 12(1):1631 (2021).